







Background: Population screening for osteoporosis using bone mineral density scan is not 5 
feasible in Malaysia as this test is costly. Hence, there is a need to develop a more efficient 6 
method to screen for osteoporosis. 7 
Objectives: To determine the feasibility of an interprofessional collaborative osteoporosis 8 
screening programme (IPC-OSP) 9 
Methods: Postmenopausal women aged ≥50 years, who had not been diagnosed with 10 
osteoporosis were recruited from a primary care clinic from June-August 2014. Patients were 11 
assessed for their osteoporosis risk and were counselled on prevention methods. Patients at risk 12 
were referred to the doctor with a recommendation for a bone mineral density (BMD) scan. 13 
Results: Fifty out of 55 patients were recruited [response rate=90.9%]. A total 26/50(52.0%) 14 
went for a BMD scan, none were osteoporotic, 17/50(34%) were osteopenic, 2/50(4.0%), were 15 
started on osteoporosis medications and 14/50(28%) modified their lifestyle to improve bone 16 
health or started on calcium supplements. Osteoporosis knowledge significantly increased from 17 
baseline to month two (46.3±21.4 vs 79.1±14.3,p<0.001). Patients had a satisfaction score of 18 
89.8±12.4. Follow-up rates were 83.9% and 100% at months 1 (BMD appointment) and 2 (phone 19 
follow up), respectively. The intervention was successfully coordinated. Data entry was 20 
determined to be viable based on the researchers’ experience. 21 
Conclusion: The IPC-OSP was found to be feasible in Malaysia. 22 
Impact on practice: 23 
- An interprofessional collaborative osteoporosis screening programme (IPC-OSP) was 24 
developed in Malaysia as it was not cost effective to perform population screening for 25 
osteoporosis using the bone mineral density scan 26 
- Interprofessional collaboration in osteoporosis screening is important as collaborative 27 
initiatives have demonstrated better patient outcomes, reduced cost and improved 28 
working relationships among health disciplines.   29 
- An interprofessional collaborative osteoporosis screening program by doctors and 30 
pharmacists was feasible when implemented in one primary care clinic in Malaysia. 31 
- However, the role of nurses was unclear as nurses may require additional training on how 32 







Introduction  37 
Approximately 20% of women who had an osteoporosis-related fracture received either a bone 38 
mineral density (BMD) scan; or were prescribed medications to treat osteoporosis within the 39 
period of six months after the fracture has occurred [1]. An interprofessional collaborative 40 
osteoporosis screening programme (IPC-OSP) was developed in Malaysia as it was not cost 41 
effective to perform population screening for osteoporosis using the bone mineral density scan.  42 
However, before an intervention can be implemented in clinical practice, the feasibility of the 43 
intervention should be determined. 44 
 45 
Aim of the study 46 
To determine the feasibility of an interprofessional collaborative osteoporosis screening 47 
programme (IPC-OSP) in a primary care clinic in Malaysia. 48 
 49 
Ethics approval 50 
Ethical approval from the University Malaya Medical Centre Ethics Committee was obtained 51 
prior to the study (ref no. 920.26). 52 
 53 
Methods 54 
Setting and participants 55 
Community-dwelling postmenopausal women aged ≥ 50 years old who had not been diagnosed 56 
with osteopenia/osteoporosis were recruited at a primary care clinic in Kuala Lumpur from June 57 
to August 2014. Participants with a history of metabolic disease, presence of bone metastasis, 58 
significant renal impairment, previous bilateral oophorectomy, history of hip fracture or prior use 59 
of bisphosphonates were excluded.  60 
 61 
Primary and secondary outcomes 62 
The typology developed by Tickle-Dengen (2013) was used to categorize the primary and 63 
secondary outcomes. Four aspects were assessed:  scientific, process, resources and management 64 





Primary outcomes 67 
Scientific assessment 68 
Our primary outcome was to measure the proportion of patients who went for a BMD scan.  69 
 70 
Secondary outcomes 71 
Scientific assessments 72 
Five secondary scientific outcomes were measured: the proportion of patients 1) diagnosed with 73 
osteoporosis/osteopenia, 2) started on osteoporosis medications, 3) who modified their lifestyle 74 
to improve bone health (by taking calcium supplements, increasing their dietary calcium or 75 
performing weight-bearing exercises), patients’ 4) who had an increase in osteoporosis 76 
knowledge and  5) who were satisfied with the IPC-OSP. 77 
 78 
Patients’ osteoporosis knowledge was measured pre- and post-intervention. Patients’ satisfaction 79 
towards the IPC-OSP was measured at the end of the feasibility study. 80 
 81 
Process assessment 82 
The intervention’s processes: such as response rates, follow-up rates, suitability of the 83 
inclusion/exclusion criteria, suitability of data collection methods, amount of patients’ time to 84 
complete the intervention and capacity to complete data collection procedures were assessed.  85 
 86 
Resource assessment 87 
The resources assessed were the coordination of intervention between nurses, pharmacists, 88 
patients and doctors, and time to conduct the intervention at each stage. Other resources assessed 89 
were the physical conditions (space and comfort), whether there was sufficient equipment 90 
available and documentation of research forms. 91 
 92 
 93 
Management assessment 94 
This was assessed by determining the accuracy of data entry and adherence to the ethics of 95 




capacity and workflow of the clinic) was used to assess the process, resource and management 97 
assessments. 98 
 99 
Instruments used  100 
Osteoporosis Self-Assessment Tool for Asians (OSTA) 101 
The validated OSTA was used to screen a patient’s risk for osteoporosis [4]. Patients were 102 
classified as low, moderate or high risk, based on their weight (in kilograms) deducted from age 103 
(in years) and multiplied by -0.2 [4]. 104 
 105 
Fracture Risk Assessment tool (FRAX) 106 
The Singapore FRAX model [5]was used to provide additional information regarding patient’s 107 
fracture risk to aid the doctor in deciding if a BMD scan was needed as the Malaysian FRAX 108 
model was not developed when our study was conducted [5].  109 
 110 
Osteoporosis Prevention and Awareness tool (OPAAT) 111 
The validated OPAAT [6] was used to assess patients’ osteoporosis knowledge. It consists of 30 112 
items categorized into three domains: osteoporosis in general, consequences of untreated 113 
osteoporosis and osteoporosis prevention. Response options were true, false, don’t know. A 114 
score of one was given for a correct response and zero for an incorrect or do not know response. 115 
A higher score indicates better knowledge. 116 
 117 
Satisfaction Questionnaire for Osteoporosis Prevention (SQOP). 118 
The validated SQOP [7] was used to assess patients’ satisfaction towards the IPC-OSP. It 119 
consists of 23 questions with a five-point Likert-type response.. Responses were categorized into 120 
six domains: outcomes/efficacy, accessibility/convenience, technical quality, interpersonal 121 
relationship, finance and continuity. A higher score indicates higher satisfaction.  122 
 123 
 124 
The Interprofessional collaborative osteoporosis screening programme (IPC-OSP)  125 
This IPC-OSP was developed from a previous qualitative study which explored the barriers and 126 




was used to analyse this data to ensure that the intervention was acceptable and sustainable[9]. 128 
Patients’ osteoporosis risk was assessed using the OSTA. The FRAX was used to provide 129 
additional information regarding the patient’s fracture risk. Patients were referred for a BMD 130 




  133 
Pharmacist conducted the first counselling session obtained baseline information, 
administered OPAAT and screened patients using OSTA and FRAX (N=50) 
 
Low risk Medium risk High risk 
Pharmacist recommended the doctor to order a BMD scan using 
a form  
Low risk & 1 risk 
factor 
Patients attended their BMD scan* 
Follow-up via phone was conducted to administer the SQOP and OPAAT. Pharmacist reminded the patients of their 
next doctor’s appointment and informed the patients of their BMD results via telephone. Questions regarding the 
BMD results and osteoporosis prevention were answered. 
 
Follow-up via phone were conducted to assess if patients attended the osteoporosis clinic or was started on 
osteoporosis treatment/preventive measures. 
Patients attended subsequent doctor’s 
appointment where their BMD results were 
reviewed 
Nurses measured the participant’s height and weight 
Doctor decided that BMD scan not 
necessary 
Doctor decided that BMD scan was 
necessary 
Doctors scheduled the next appointment one 
month later  
*The patients and the researcher received a copy of the results. Abbreviations: 
- BMD: Bone Mineral Density 
- OSTA: Osteoporosis Self-Assessment Tool for Asians 
- OPAAT: Osteoporosis Prevention and Awareness Tool 
- SQOP: Satisfaction Questionnaire for Osteoporosis Prevention 
- FRAX- WHO Fracture Risk Assessment tool 
Nurses referred potential candidates to the pharmacist 




Data Analysis 134 
All data was entered into the IBM® SPSS® version 20 (IBM Corporation, Armonk, NY, US). 135 
Non-parametric tests were used since data obtained were not normally distributed.  Categorical 136 
variables were presented as proportion. Continuous variables were presented as median and 137 
interquartile range. McNemar’s test was used to examine the pre and post scores of the 138 
individual items in the OPAAT. A p-value <0.05 was considered as statistically significant. 139 
 140 
Results 141 
A total of 50/55 patients agreed to participate (response rate= 90.9%). A total of 36/50(72%) 142 
patients were referred for a BMD scan, of which only 28/36(77.8%) recommendations were 143 
accepted by the doctor. additionally, 3 scans were ordered without the pharmacist’s 144 
recommendation, as these scans were provided “free of charge”.  A total to 31/36 (86.1%) BMD 145 
scans were ordered. Reasons provided by the doctors on why BMD scans were not ordered were: 146 
3/36(8.3%) patients’ x-ray results were normal; 1/36(2.8%) doctor said that there were more 147 
urgent diseases to treat such as heart, endocrine or eye conditions; 1/36(2.8%) patient’s blood 148 
calcium levels were normal; 1/36(2.8%) patient was  “too young”; 1/36(2.8%) patient’s FRAX 149 
fracture risk was considered too low (11% major osteoporosis fracture and 2.2% for hip 150 
fracture), and 1/36(2.8%) would be exposed to too much radiation as she had another 151 
appointment for a computed tomography (CT) scan. Ultimately, 26/31(83.9%) went for a BMD 152 


















































Patients screened at the waiting area, n=55 
Patients recruited by the pharmacist, n=50 (response rate 90.9%) 
Baseline information, clinical risk factors was collected. FRAX, 
OSTA and the OPAAT were administered. 
High risk, n=9 (18.0%) 
Patients recommended for BMD scan, n=36 (72.0%) 
Declined (n=5) 




Moderate risk, n=18 (36.0%) Low risk, n=23 (46.0%) 
 No. of patients with >1 major 
risk factors, n= 9 (39.1%) 
BMD scans were ordered based on the recommendations and doctors’ evaluation, n=31 (86.1%) 
Patients that went for BMD scan, n=26 (83.9%) 
Patients that did not go for BMD scan 
n=5 (16.1%) 
BMD results reviewed by PCP, n=25 (96.2%) Patient did not go for PCP appointment, 
n=1 (3.8%) 
Normal, n=9 (36.0%) Osteopenia, n=16 (64.0%) 
No action by 








No action by 
PCP, n= 10 
(62.4%) 
Private PCP started patients on osteoporosis 


































OSTA= Osteoporosis screening 
tool for Asians 
BMD= Bone mineral density 
PCP- Primary care physicians 
Figure 2: Results of the feasibility study 
 
Abbreviations: 
OSTA-Osteoporosis Self-Assessment Tool for Asians 
BMD-Bone mineral density 
PCP-Primary care physician 
 
Notes: 
* Patient had inappropriate parathyroid levels,  





Seventeen out of the 26 patients who went for the BMD scan (65.4%) had osteopenia whilst 166 
none had osteoporosis; of which 2/26(7.7%) patients were started on strontium. Among those 167 
patients who had a normal BMD scan or osteopenia (n=26), 11 (42.3%) were started on calcium 168 
supplements and 3/26 (11.5%) modified their lifestyle to improve bone health (Figure 2). 169 
 170 
 171 
Only 46/50 patients answered the OPAAT at baseline and one month later (response 172 
rate=92.0%). All three domains showed an increase in osteoporosis knowledge: osteoporosis in 173 
general (44.7±28.0 to 73.5±26.0), consequences of untreated osteoporosis (50.8±26.9 to 174 
93.9±11.8) and prevention of osteoporosis (46.0±25.1 to 79.7±16.2). Overall, knowledge 175 
increased from 46.3±21.4 to 79.1±14.3, p <0.001. Knowledge increased in 27/30(90.0%) items. 176 
One month later, patients’ satisfaction score was 89.8±12.4.  177 
 178 
Based on the response rate of 90.9% we found the inclusion criteria to be suitable. The follow-up 179 
rate was 26/31(83.9%) during the first follow-up and 26/26(100%) for the second follow-up.  180 
 181 
Resource assessment 182 
The pharmacist initially found it difficult to communicate her recommendations and procedures 183 
to the doctor. In order to resolve this, the pharmacist conducted individual briefing sessions with 184 
the doctors. 185 
 186 
The pharmacist found that the risk assessment, counselling and administration of the OPAAT 187 
approximately 30 minutes for each patient. The time allocated was sufficient as patients usually 188 
had to wait at least 30 minutes before being called to see the doctor. For the first follow-up 189 
session, the administration of the OPAAT, SQOP and information on the BMD results took 190 
approximately 15-30 minutes depending on the number of questions the patients had. The second 191 
follow-up needed about five minutes. 192 
 193 
Documentation was successful. The forms used by the pharmacists to make recommendations 194 
were documented into the patients’ medical record. Equipment to measure BMD, height and 195 




Management assessment 198 
The pharmacist was able to document all data and outcomes needed into SPSS daily. There were 199 
also no problems with managing the procedures based on the ethics application. 200 
 201 
Discussion 202 
The current workflow was feasible, as both primary and secondary outcomes could be assessed. 203 
Our results concurred with previous osteoporosis screening programmes which showed an 204 
increase in BMD scans ordered, and initiation of calcium supplements and/or treatment [10]. 205 
 206 
Initially, the pharmacist had difficulty conveying recommendations to the doctor, and the nurses 207 
had difficulty screening for osteoporosis patients. Hence, modifications were made. The 208 
pharmacist screened for potential patients herself and this improved the feasibility of the IPC-209 
OSP.  210 
 211 
The satisfaction score of the patients were 89.8±12.4. This score was similar to the score 212 
achieved by the intervention group of the SQOP validation study which was 87.9±6.0. Based on 213 
this previous study the cut-off score was defined as 61.0 as the control group in this study 214 
achieved a satisfaction score of 61.9±8.-8[7]. 215 
 216 
Following the process assessments of the IPC-OSP, modifications were made to the data 217 
collection method. Initially, nurses were asked to refer potential patients to the pharmacists. This 218 
method was inefficient as nurses did not know how to screen patients as they were not trained to 219 
screen patients for osteoporosis. The pharmacist then screened for potential patients herself. Our 220 
findings were similar to a study in the United States, which found that the osteoporosis screening 221 
program performed better when it was conducted by a clinical-pharmacist , as opposed to a 222 
registered-nursed[11]. A training session pertaining to the IPC-OSP should be conducted for 223 





A limitation of this study was that the sample size used was small and results were not 227 
generalisable. However, the aim of this study was not to assess the effectiveness of the 228 
intervention. Therefore, we achieved the aim of our study, which was to assess the feasibility of 229 
the developed interprofessional collaborative osteoporosis screening programme. A further 230 
limitation of this study was the exclusion of men. It is possible that different psychological 231 
factors are related to the screening of osteoporosis in men, which need to be explored further.  232 
 233 
The strength of this study was that the IPC-OSP was designed specifically for this setting 234 
following a qualitative study [8]. It was then supported by the use of the behavioural change 235 
wheel to ensure that the underlying psychological reason to conducting an osteoporosis screening 236 
programme was addressed [9]. Additionally, the instruments used (i.e. the OPAAT and the 237 
SQOP) were specifically developed and validated for this intervention [6, 7]. Furthermore, the 238 
IPC-OSP was coordinated by a pharmacist. The inclusion of pharmacists into healthcare delivery 239 
teams in literature have noted improved health outcomes in osteoporosis [12]. 240 
 241 
Conclusion 242 
The IPC-OSP was found to be feasible when assessed in a primary care setting in Malaysia. 243 
However, a feasibility study does not assess the effectiveness of the IPC-OSP. A randomized 244 
controlled trial would be needed to determine if the IPC-OSP would improve patient outcomes 245 
such as reducing the number of osteoporotic-related fractures.  246 
 247 
 248 
Conflicts of interest: Li Shean Toh, Pauline Siew Mei Lai, Bee Yean Low, Kok Thong Wong, 249 
and Claire Anderson declare that they have no conflict of interest. 250 
 251 









1. Cosman F, Lindsay R, LeBoff MS, Jan de Beur S, Tanner B. National Osteoporosis Foundation. 259 
Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis 260 
Foundation; 2014. 261 
2. Tickle-Degnen L. Nuts and bolts of conducting feasibility studies. The American Journal of 262 
Occupational Therapy. 2013(67):171-6. doi:10.5014/ajot.2013.006270. 263 
3. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP et al. A tutorial on pilot studies: the what, why and 264 
how. BMC Medical Research Methodology. 2010;10(1):1. doi:10.1186/1471-2288-10-1. 265 
4. Koh LKH, Sedrine WB, Torralba TP, Kung AW, Fujiwara S, Chan SP et al. A simple tool to identify Asian 266 
women at increased risk of osteoporosis. Osteoporosis international. 2001;12:699-705.  267 
5. Kanis JA. FRAX WHO Fracture Risk Assessment Tool. World Health Organization Collaborating Centre 268 
for Metabolic Bone Diseases, University of Sheffield, UK. 2014. http://www.shef.ac.uk/FRAX/. Accessed 269 
22 December 2014. 270 
6. Toh LS, Lai PS, Wu DB, Wong KT, Low BY, Anderson C. The Development and Validation of the 271 
Osteoporosis Prevention and Awareness Tool (OPAAT) in Malaysia. PLoS One. 2015;10(5):e0124553. 272 
doi:10.1371/journal.pone.0124553. 273 
7. Toh LS, Lai PSM, Wong KT, Tan ATB, Low BY, Anderson C et al. The development and validation of the 274 
Satisfaction Questionnaire for Osteoporosis Prevention in Malaysia. Patient Preference and Adherence. 275 
2014;8:1365-81. doi:10.2147/ppa.s65718. 276 
8. Toh LS, Lai PSM, Wong KT, Low BY, Anderson C. What are the barriers encountered while screening 277 
for osteoporosis in a government university hospital primary care setting? Preliminary results of a 278 
qualitative study on Malaysian nurses views. Osteoporosis international. 2012;23(Suppl 7):S777.  279 
9. Toh LS, Lai PSM, Low BY, Wong KT, Anderson C. The development of a pharmacist-led osteoporosis 280 
screening intervention using the behavioural change wheel. International Journal of Pharmacy Practice. 281 
2016:30.  282 
10. Elias MN, Burden AM, Cadarette SM. The impact of pharmacist interventions on osteoporosis 283 
management: a systematic review. Osteoporosis international. 2011;22(10):2587-96. 284 
doi:10.1007/s00198-011-1661-7. 285 
11. Heilmann RMF, Friesleben CR, Billups SJ. Impact of a pharmacist-directed intervention in 286 
postmenopausal women after fracture. American Journal of Health-System Pharmacy. 2012;69(6):504-9. 287 
doi:10.2146/ajhp110309. 288 
12. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for 289 
osteoporosis: randomized controlled trial. Osteoporosis international. 2010;21(3):391-8. 290 
doi:10.1007/s00198-009-0977-z. 291 
 292 
